Effectiveness of bortezomib in multiple myeloma: Preliminary results from an international electronic observational study

被引：0
|
作者：
Delforge, M. [1 ]
Katodritou, E. [2 ]
Zervas, K. [2 ]
Sargin, D. [3 ]
Hulin, C. [4 ]
Linderholm, M. [5 ]
Verrou, E. [2 ]
Poon, V [6 ]
Dhawan, R. [6 ]
机构：
[1] Katholieke Univ Leuven Hosp, Louvain, Belgium
[2] Theagenion Canc Ctr, Thessaloniki, Greece
[3] Istanbul Univ, Istanbul, Turkey
[4] CHU NANCY Brabois, Nancy, France
[5] Linkoping Univ Hosp, S-58185 Linkoping, Sweden
[6] Johnson & Johnson Pharmaceut Serv, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70183-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A55 / A55
页数：1
相关论文
共 50 条
  • [31] Bortezomib (Velcade™) observational study in China -: Efficacy and safety of bortezomib based regimen in 223 relapsed or refractory multiple myeloma patients
    Shen, Zhi-xiang
    BLOOD, 2007, 110 (11) : 282B - 283B
  • [32] Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis
    Sebag, Michael
    Stakiw, Julie
    Stephens, Thomas J.
    Padhiar, Amie
    Kim, Tony
    Shum, Jane
    Dhanasiri, Sujith
    Trudel, Suzanne
    BLOOD, 2019, 134
  • [33] Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium
    Schinasi, Leah H.
    Brown, Elizabeth E.
    Camp, Nicola J.
    Wang, Sophia S.
    Hofmann, Jonathan N.
    Chiu, Brian C.
    Miligi, Lucia
    Freeman, Laura E. Beane
    de Sanjose, Silvia
    Bernstein, Leslie
    Monnereau, Alain
    Clavel, Jacqueline
    Tricot, Guido J.
    Atanackovic, Djordje
    Cocco, Pierluigi
    Orsi, Laurent
    Dosman, James A.
    McLaughlin, John R.
    Purdue, Mark P.
    Cozen, Wendy
    Spinelli, John J.
    de Roos, Anneclaire J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (01) : 87 - 101
  • [34] Phase III results of bortezomib in previously untreated multiple myeloma
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (10) : 1543 - 1543
  • [35] Bortezomib with dexamethasone as induction therapy in newly diagnosed multiple myeloma: A preliminary study in Thai patients
    Nakorn, T. Na
    Watanaboonyongcharoen, P.
    Nipharak, P.
    Chancharunee, S.
    Intragumtornchai, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 181 - 181
  • [36] Multiple myeloma:: Increase of the effectiveness of Velcade® (Bortezomib) through combination therapy
    Aschoff, K
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2005, 32 (05) : 284 - 284
  • [37] Cost-effectiveness of bortezomib (VELCADE) for relapsed and refractory multiple myeloma
    Bagust, A
    Haycox, A
    Mujica-Mota, R
    Dhawan, R
    Dubois, D
    VALUE IN HEALTH, 2004, 7 (06) : 670 - 670
  • [38] THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN SWEDEN
    Rickert, J. B.
    Hornberger, J.
    Dhawan, R.
    Liwing, J.
    Aschan, J.
    Lothgren, M.
    VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
  • [39] Multiple myeloma:: Increase of the effectiveness of Velcade® (Bortezomib) through combination therapy
    不详
    ONKOLOGIE, 2005, 28 (11): : 608 - 608
  • [40] Peripheral Neuropathy as Assessed in an International Observational Study of Bortezomib
    Delforge, M.
    Dhawan, R.
    De Samblanx, H.
    Zervas, K.
    Sargon, Deniz
    Hulin, C.
    Linderholm, M.
    de la Rubia, J.
    Abdulkadyrov, K.
    Gunguly, R.
    Diels, J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S21 - S22
12345